Podcasts

OUTSPOKEN ONCOLOGY

Episode 48: Overcoming Challenges of Clinical Research in the Community

05/03/2022

Michael Thompson, MD, PhD, Advocate Aurora Health Care, discusses social determinants of health, eligibility criteria, and other barriers to clinical trial enrollment in the community setting, as well as the importance of real-world evidence...

Michael Thompson, MD, PhD,...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 47: The Global Oncology Agenda With Gilberto Lopes

05/03/2022

Gilberto Lopes, MD, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other topics.

Gilberto Lopes, MD, discusses...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 45: Simplifying Biosimilars With Gary Lyman

05/03/2022

Gary Lyman, MD, MPH, details why it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice and touches on issues of granting extrapolation.

Gary Lyman, MD, MPH, details why...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 44: Payer's Approach to Social Determinants of Health

05/03/2022

Andrew Renda, MD, associate vice president of population health at Humana, discusses ways in which Humana designs supplemental benefits for social needs as well as addresses social determinants of health to close clinical gaps in care.

Andrew Renda, MD, associate vice...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 43: Chasing My Cure With David Fajgenbaum

05/03/2022

David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of "Chasing My Cure," discusses treating his own disease through experimental self-administered therapies and involvement in developing the first NCCN guidelines and...

David Fajgenbaum, MD, MBA, MSc,...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 42: Updates and Controversies in CML With Matt Kalaycio

05/03/2022

Matt Kalaycio, MD, Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics.

Matt Kalaycio, MD, Cleveland...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 41: Mitigating Cancer-Related Financial Toxicity With Carla Tardif

05/03/2022

Carla Tardif, CEO of Family Reach, discusses the personal expenses that patients with cancer and their families are burdened with aside from medical care as well as the ways in which Family Reach is offering financial support for these...

Carla Tardif, CEO of Family...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 40: Caregivers in Cancer Care: The "Overlooked Ones"

05/03/2022

Anita Gruninger, RN and certified case manager, provides the often-forgotten perspective of a caregiver, including the emotional and financial toll a cancer diagnosis has on patients and their caregivers as well as the struggles of navigating...

Anita Gruninger, RN and...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 39: Advances in Renal Cell Carcinoma With Toni Choueiri

05/03/2022

Toni Choueiri, MD, discusses surgical considerations and multidisciplinary care for localized kidney cancer, adjuvant therapies largely falling short of expectations, and the plethora of frontline therapies available in metastatic disease.

Toni Choueiri, MD, discusses...

05/03/2022

Journal of Clinical Pathways

OUTSPOKEN ONCOLOGY

Episode 38: Social Media and Medicine With Aaron Gerds

05/03/2022

Aaron Gerds, MD, department of hematology and medical oncology, Cleveland Clinic, describes the benefits and pitfalls of Twitter as a platform for doctors to share their ideas and engage in the "ultimate peer-review process."

Aaron Gerds, MD, department of...

05/03/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

79458

Recent Stories

Videos

Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies

11/14/2024

Sawsan Rashdan , MD;

Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.

Dr. Sawsan Rashdan, an associate...

11/14/2024

Journal of Clinical Pathways

News

Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy

11/13/2024

Hannah Musick ;

Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...

Combining immunotherapy with...

11/13/2024

Journal of Clinical Pathways

News

Under 50% of Oncology Practices Offer Survivorship Clinics

11/12/2024

Jolynn Tumolo ;

Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.

Just 41% of oncology practice...

11/12/2024

Journal of Clinical Pathways

Videos

Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams

11/12/2024

Shaffee Bacchus , PharmD;

Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...

Shaffee Bacchus, PharmD,...

11/12/2024

Journal of Clinical Pathways

Videos

Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up

11/08/2024

;

Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...

Kerry Rogers, MD, provides a...

11/08/2024

Journal of Clinical Pathways

Podcasts

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products